2. Signaling Pathways
  3. Neuronal Signaling
  4. Amyloid-β

Amyloid-β

β-amyloid peptide; Aβ; Abeta

Amyloid-β

Related Products

PDF 1.52 MB

Amyloid-β (Aβ) denotes peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease as the main component of theamyloid plaques found in the brains of Alzheimer patients. The peptides result from the amyloid precursor protein (APP), which is being cut by certain enzymes to yield Aβ. Amyloid-β molecules can aggregate to form flexible soluble oligomers which may exist in several forms. Amyloid-β peptide is due to overproduction of Aβ and/or the failure of clearance mechanisms. Amyloid-β self-aggregates into oligomers, which can be of various sizes, and forms diffuse and neuritic plaques in the parenchyma and blood vessels. Amyloid-β oligomers and plaques are potent synaptotoxins, block proteasome function, inhibit mitochondrial activity, alter intracellular Ca2+levels and stimulate inflammatory processes. Loss of the normal physiological functions of Aβ is also thought to contribute to neuronal dysfunction.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-105252A
    BF 227
    		98.97%
    BF 227 is a candidate for an amyloid imaging probe for PET, with a Ki of 4.3 nM for Aβ1-42 fibrils.
    BF 227
  • HY-P10935A
    Amilo-5MER TFA
    		Inhibitor 99.63%
    Amilo-5MER (5-MP) TFA is an orally active and selective Serum Amyloid A (SAA) inhibitor. Amilo-5MER TFA specifically inhibits the release of pro-inflammatory cytokines IL-6 and IL-1β from SAA-activated cells. Amilo-5MER TFA reduces chronic inflammation and relieves symptoms of diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and multiple sclerosis (MS). Amilo-5MER TFA is promising for research of autoimmune diseases and chronic inflammatory diseases.
    Amilo-5MER TFA
  • HY-P3688A
    β-Amyloid (1-38) TFA
    		99.38%
    β-Amyloid (1-38) (Aβ (1-38)) TFA is a β-Amyloid (Aβ) peptide. β-Amyloid (1-38) TFA interferes with the conversion of Aβ(1-42) to a β-sheet-rich aggregate. β-Amyloid (1-38)TFA reverses the negative impact of Aβ(1-42) on long-term potentiation in acute hippocampal slices and on membrane conductance in primary neurons, and mitigates an Aβ(1-42) phenotype in Caenorhabditis elegans.
    β-Amyloid (1-38) TFA
  • HY-176293
    EP2 receptor antagonist-3
    		Inhibitor 99.08%
    EP2 receptor antagonist-3 is a selective EP2 receptor antagonist (IC50: 8 nM in hEP2 SPA assay, 50 nM in hEP2 cAMP assay). EP2 receptor antagonist-3 increases the macrophage-mediated clearance of Amyloid-β plaques. EP2 receptor antagonist-3 can be used for the study of alzheimer’s diseases.
    EP2 receptor antagonist-3
  • HY-P1146A
    Semax acetate
    		Inhibitor 99.39%
    Semax acetate is a BBB-penetrable adrenocorticotropic hormone-like peptide and can form stable complexes with Cu2+. Semax acetate is a synthetic peptide analog of Adrenocorticotropic hormone (ACTH) (4-10). Semax acetate has immunomodulatory, nootropic and neuroprotective activities. Semax acetate can be used in the research of central nervous system diseases such as Alzheimer's disease and cerebral ischemia.
    Semax acetate
  • HY-N2580
    Zinc Phytate
    		Inhibitor 98.20%
    Zinc Phytate (myo-Inositol; hexakis dihydrogen phosphate; Inositol hexaphosphate) is an orally active compound. Zinc Phytate can be derived from the seeds of legumes. Zinc Phytate is a [PO4]3- storage depot and precursor for other inositol phosphates and pyrophosphates. Zinc Phytate attenuates Aβ oligomers and upregulates autophagy protein. Zinc Phytate can be used in cardiovascular disease, metabolic disease, nervous system disease and cancer research.
    Zinc Phytate
  • HY-150003
    Aβ1–42 aggregation inhibitor 1
    		Inhibitor 99.19%
    Aβ1-42 aggregation inhibitor 1 inhibits AChE (acetylcholinesterase) and BuChE (butyrylcholinesterase) with the IC50 value of 2.64 μM and 1.29 μM, respectively. Aβ1-42 aggregation inhibitor 1 inhibits self-mediated Aβ1-42 aggregation by 51.29% at a concentration of 25 μM. Aβ1-42 aggregation inhibitor 1 has the potential for the research of anti-Alzheimer's disease.
    Aβ1–42 aggregation inhibitor 1
  • HY-138643
    Cl-NQTrp
    		99.97%
    Cl-NQTrp signifcantly disrupts the preformed fbrillar aggregates of Tau-derived PHF6 (VQIVYK) peptide and full-length tau protein.
    Cl-NQTrp
  • HY-114508
    Dihydrochalcone
    		Inhibitor 99.87%
    Dihydrochalcone (3-Phenylpropiophenone) is a Aβ aggregation inhibitor. Dihydrochalcone destabilizes Aβ17-42 protofibrils by disrupting the β-sheet of β1 region. Dihydrochalcone destabilizes both U-shaped Aβ40/Aβ42 protofibrils and S-shaped Aβ42 protofibrils by binding to the protofibril cavity. Dihydrochalcone is the main component of daemonorops draco tree.
    Dihydrochalcone
  • HY-171347
    gamma-secretase modulator 6
    		Inhibitor 99.68%
    gamma-secretase modulator 6 (Example 50) is a gamma-secretase modulator. gamma-secretase modulator 6 inhibits Aβ42 secretion in HEK cell line stably expressing APP (Aβ amyloid precursor protein) (pIC50: 8.1). gamma-secretase modulator 6 can be used for research of Alzheimer's disease.
    gamma-secretase modulator 6
  • HY-B0104R
    Glimepiride (Standard)
    		Inhibitor
    Glimepiride (Standard) is the analytical standard of Glimepiride. This product is intended for research and analytical applications. Glimepiride (Glimperide) is a medium-to-long acting sulfonylurea anti-diabetic compound with an ED50 of 182 μg/kg.
    Glimepiride (Standard)
  • HY-101861
    Miridesap
    		Inhibitor 99.19%
    Miridesap is a ligand for serum amyloid P component (SAP) and intends to inhibit and dissociate SAP binding to amyloid fibrils and tangles.
    Miridesap
  • HY-P990011
    Sabirnetug
    		Inhibitor
    Sabirnetug is a humanized IgG2κ antibody targeting the Amyloid-β A4 precursor protein.
    Sabirnetug
  • HY-115726
    FRM-024
    		Inhibitor 99.45%
    FRM-024 is a central nervous system-penetrant, orally active γ-secretase modulator and Aβ42 lowering agent. FRM-024 is used for the research of familial Alzheimer's disease.
    FRM-024
  • HY-161078
    QP5038
    		99.51%
    QP5038 (compound 28) is an inhibitor of QPCTL with an IC50 value of 3.8 nM. QP5038 has antitumor efficacy.
    QP5038
  • HY-P0128F
    FITC-β-Amyloid (25-35)
    		99.40%
    FITC-β-Amyloid (25-35) is a FITC (HY-66019) labeled β-Amyloid (25-35) (HY-P0128)
    FITC-β-Amyloid (25-35)
  • HY-113788
    PF-719
    		Inhibitor 99.52%
    PF-719 is a highly selective Pyk2 inhibitor with an IC50 value of 17 nM. PF-719 promotes the activation of LKB1 and p38 MAPK. PF-719 blocks synaptic deficits induced by Amyloid-beta oligomers and reverses the inhibition of long-term potentiation induced by β-amyloid oligomers. PF-719 can be used in research related to Alzheimer's disease and autoimmune diseases.
    PF-719
  • HY-128849
    Eprodisate (70% in water)
    		Inhibitor ≥98.0%
    Eprodisate (70% in water) is an amyloid inhibitor that interferes with the interaction between amyloidogenic proteins and glycosaminoglycans, thereby inhibiting the aggregation of amyloid fibrils and the deposition of fibrils in tissues. Eprodisate (70% in water) slows the progression of renal disease associated with AA amyloidosis and may be useful for other types of amyloidosis.
    Eprodisate (70% in water)
  • HY-P1363F1
    Biotin-β-Amyloid (1-42), human TFA
    		99.01%
    Biotin-β-Amyloid (1-42), human TFA (Biotin-Amyloid β-Peptide (1-42) (human) TFA) is the botin labeled β-Amyloid (1-42), human TFA (HY-P1363). β-Amyloid (1-42), human TFA is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease.
    Biotin-β-Amyloid (1-42), human TFA
  • HY-162043
    CKR-49-17
    		Degrader 98.40%
    CKR-49-17 is an activator of CK1γ2. CKR-49-17 decreases C99 and β-amyloid levels. CKR-49-17 can be used in the research of Alzheimer's disease (AD).
    CKR-49-17
Cat. No. Product Name / Synonyms Application Reactivity